Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 442,934 | 399,356 | 611,091 | 744,856 | 658,412 |
| Cost of Goods | 398,708 | 150,775 | 152,558 | 137,564 | 132,304 |
| Gross Profit | 44,226 | 248,581 | 458,533 | 607,292 | 526,108 |
| Operating Expenses | 456,517 | 352,745 | 343,514 | 908,242 | 364,731 |
| Operating Income | -411,583 | -103,389 | 115,577 | -300,386 | 161,681 |
| Other Income | 133,287 | -90,660 | 38,061 | -83,132 | 10,062 |
| Pre-tax Income | -278,296 | -194,049 | 153,638 | -383,518 | 171,743 |
| Income Tax | 4,551 | -14,102 | -43,254 | 63,990 | 12,694 |
| Net Income Continuous | -282,847 | -179,947 | 196,892 | -447,508 | 159,049 |
| Net Income | $-282,847 | $-179,947 | $196,892 | $-447,508 | $159,049 |
| EPS Basic Total Ops | -2.74 | -1.80 | 2.01 | -4.60 | 1.67 |
| EPS Basic Continuous Ops | -2.74 | -1.80 | 2.01 | -4.60 | 1.67 |
| EPS Diluted Total Ops | -2.62 | -1.80 | 1.89 | -4.60 | 1.56 |
| EPS Diluted Continuous Ops | -2.58 | -1.80 | 1.85 | -4.60 | 1.42 |
| EPS Diluted Before Non-Recurring Items | -3.87 | -0.28 | 1.70 | -3.84 | 1.50 |
| EBITDA(a) | $-406,710 | $-86,072 | $124,551 | $-292,320 | $165,333 |